Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis
Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis
About this item
Full title
Author / Creator
Publisher
Boston, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Boston, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Meta-analyses suggest that the thiazolidinedione rosiglitazone, used in the treatment of type 2 diabetes, may increase the risk of myocardial infarction and death from cardiovascular causes. This interim analysis of an ongoing noninferiority trial of rosiglitazone is inconclusive but does not exclude cardiotoxicity. Because patients with diabetes a...
Alternative Titles
Full title
Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_223921117
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_223921117
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa073394
